Biogen (BIIB) Earning Somewhat Favorable Press Coverage, Study Finds
News headlines about Biogen (NASDAQ:BIIB) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Biogen earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.9876491487658 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news stories that may have impacted Accern’s analysis:
- Better Buy: Biogen Inc. vs. Gilead Sciences (fool.com)
- Biogen Inc. (BIIB) Receives Consensus Recommendation of “Buy” from Brokerages (americanbankingnews.com)
- If An Alzheimer’s Drug Succeeds, Could Our Health System Handle It? (finance.yahoo.com)
- Innovative stocks: FireEye, Inc., (NASDAQ: FEYE), Biogen Inc., (NASDAQ: BIIB), AK Steel Holding Corporation, (NYSE … – Stocks In The News (press release) (tradingnewsnow.com)
- Biogen (BIIB) a Hold on Feeble Quant Score – Investorplace.com (investorplace.com)
BIIB has been the subject of several recent research reports. Citigroup Inc. cut shares of Biogen from a “buy” rating to a “neutral” rating in a report on Monday, October 23rd. Vetr lowered shares of Biogen from a “strong-buy” rating to a “buy” rating and set a $319.53 price target on the stock. in a research report on Wednesday, August 23rd. Stifel Nicolaus reaffirmed a “hold” rating and set a $300.00 price target on shares of Biogen in a research report on Thursday, October 12th. Mizuho set a $400.00 price target on shares of Biogen and gave the stock a “buy” rating in a research report on Monday, November 13th. Finally, Robert W. Baird reaffirmed a “hold” rating and set a $290.00 price target on shares of Biogen in a research report on Friday, August 25th. Twelve analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Biogen currently has an average rating of “Buy” and a consensus target price of $341.89.
Biogen (NASDAQ:BIIB) traded down $3.47 during trading hours on Monday, reaching $310.51. 353,422 shares of the company traded hands, compared to its average volume of 1,509,567. The company has a current ratio of 2.19, a quick ratio of 1.90 and a debt-to-equity ratio of 0.46. Biogen has a twelve month low of $244.28 and a twelve month high of $348.84. The firm has a market cap of $65,790.00, a P/E ratio of 14.54, a PEG ratio of 1.96 and a beta of 0.72.
Biogen (NASDAQ:BIIB) last posted its earnings results on Tuesday, October 24th. The biotechnology company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.70 by $0.61. Biogen had a net margin of 29.44% and a return on equity of 38.51%. The business had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same period last year, the company earned $5.19 EPS. The firm’s revenue was up 4.1% compared to the same quarter last year. equities analysts predict that Biogen will post 22.03 earnings per share for the current fiscal year.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Stock Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related stocks with our FREE daily email newsletter.